We all are in the middle of a pandemic and because of this almost all of us are today confined to our homes. Maintaining a healthy heart is important during and after the coronavirus pandemic.
Owing to the accessibility challenges to quality healthcare in the country and Covid related infection fears, the portable and technology-enabled ECG device will help deliver affordable and convenient heart care to over 260 million heart patients and those at risk, without visiting a hospital.
AliveCor, the global leader in US FDA-cleared personal electrocardiogram (ECG) technology, today announced its entry in the Indian market with the revolutionary launch of the most clinically-validated personal ECG device, KardiaMobile 6L.
KardiaMobile 6L is the only personal ECG device in the world that can detect the three most common arrhythmias or irregular heartbeat—atrial fibrillation (AFib), bradycardia, and tachycardia, which require regular monitoring and a healthy lifestyle.
Across the world, cardiovascular disease (CVD) is the leading cause of mortality. According to The Lancet report, an estimated 54.5 million people are affected by CVD in India, leading to one in four deaths. Reports also suggest that arrhythmias, like AFib, affect an estimated 10 million people in India and are leading indicators of heart disease and stroke.
AliveCor’s innovative technology gives patients the ability to record a medical-grade ECG in just 30 seconds, with no hospital visits and complete peace of mind. The device is small enough to fit in a pocket, allowing users to check in on their hearts anytime, anywhere right from their smartphone.
In a country like India where over 70% of the population owns a smartphone, this technology comes as a big boost to make heart care accessible, affordable, and convenient.
Considering the ongoing health crisis, the use of KardiaMobile 6L reassures optimal clinical control and caters to the need for efficient tools for safe out-of-hospital management. For patients with pre-existing conditions or those who feel a symptom, it provides convenience to track heart health on-the-go without hospital visits.
Priya Abani, Chief Executive Officer, AliveCor mentioned, “With hundreds of millions at risk for heart disease across the globe, accessible heart care has never been more important. AliveCor’s expansion into India is pivotal to our mission of providing remote, medical-grade heart care to those who need it most. We are committed to innovating digital health services in India by offering patients the ability to take control of their own heart health from the comfort of home.”
As digital health emerges as a key objective for India where healthcare accessibility is a concern, mobile healthcare through a device like KardiaMobile 6L bears the utmost value. Early detection of arrhythmias is critical, and through the launch of KardiaMobile 6L, AliveCor puts the power of early detection directly into the hands of patients in India.
AliveCor’s KardiaMobile 6L is priced at INR 14,000 and KardiaMobile is priced at INR 8,500. They are available for purchase at alivecor.in.